Armed Oncolytic Immunotherapies Summit

Armed Oncolytic Immunotherapies Summit is organized by Hanson Wade and will be held during Jun 26 - 28, 2018 at Le Meridien Parkhotel Frankfurt, Frankfurt, Hessen, Germany.

Explore the next generation of armed oncolytic immunotherapies in combination which have the greatest potential for clinical and commercial success.

The Armed Oncolytic Immunotherapy Summit is your opportunity to hear the most up-to-date clinical advances alongside novel therapeutic strategies to increase potency, targeting and immune cell recruitment, in the effort to turn cold tumours hot.

Why you should attend:
• Arming – Enhance the lytic potential of oncolytic viruses and microbes by genetically arming the virus with multiple payloads. Exploit the transportation of these viruses and use these potential vehicles to increase potency.
• Combinations – Explore the current clinical landscape and identify the most rational combinations to augment current therapies, enhancing trafficking into the tumour microenvironment alongside heightened immune system recruitment, turning cold tumours hot.
• Manufacturing – Join the leading industry experts as we translate these innovative approaches into the clinic and build strategies to future-proof and scale-up the process development of your therapies; ensuring quantity and quality of virus and microbe production.
• Systemic Delivery – Explore the hurdles surrounding intratumoral delivery and join the discussion to overcome the challenge in facilitating an un-invasive delivery system that is able to travel intravenously to the tumour site and overcome the immune system response.

Prices:
Conference + 2 Workshops Earlybird (Book by 23/03/18): EUR 2297
Conference + 2 Workshops (standard rate): EUR 2597
Conference + 1 Workshop Earlybird (Book by 23/03/18): EUR 1898
Conference + 1 Workshop (standard rate): EUR 2198
Conference Earlybird (Book by 23/03/18): EUR 1399
Conference (Standard rate): EUR 1799
Workshop only: EUR 499

Speakers: Akseli Hemminki (TILT Biotherapeutics), Daniel Katzman (Unleash Immuno Oncolytics), Colin Love (Replimune), Gabriella Campadelli-Fiume (NousCom), Frank Tufaro (DNAtrix), Stephen Russell (Vyriad)

Additional details will be posted as soon as they are available.